Open AccessAnti‐PD ‐1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer: A case report
Author(s) -
Ren Wei,
Wu Puyuan,
Tian Jing,
Chen Dongsheng,
Li Si,
Liu Baorui
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13735
Subject(s) - medicine , immunotherapy , chemotherapy , oncology , regimen , esophageal cancer , clinical trial , cancer , surgery
The prognosis of the small cell esophageal cancer (SCEC) patient in our study was poor due to lack of treatment options which were limited to surgery and chemotherapies, with a median overall survival (OS) of only 11.1 months according to previous studies. Herein, we adopted the regimen of immunotherapy plus chemotherapy, which exerted superior and durable benefit (OS > 19 months) in the patient in our study. Immunotherapy plus chemotherapy might therefore be a reasonable option for selected SCEC patients. In addition, well‐designed trials for better evidence are required to verify the findings in this study.